PAI LIFE SCIENCES, INC.

Company Information
Address 1616 EASTLAKE AVE E STE 550
SEATTLE, WA, 98102-3788

http://www.pailifesciences.com

Information

DUNS: 148051621

# of Employees: 6


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus

    Amount: $224,998.00

    PROJECT SUMMARY ABSTRACT Chikungunya virus CHIKV is an emerging disease of global public health importance Originally identified in sporadic CHIKV outbreaks occurred in Africa and Asia for s ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. CruziScreen, a recombinant antigen-based screening test for Chagas disease

    Amount: $157,401.00

    Project Summary Chagas disease is a severe inflammatory syndrome caused by infection with a protozoan parasite Trypanosoma cruzi Although transmission occurs mostly through an intermediate insect ho ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  3. A recombinant protein that increases engraftment of hematopoietic stem cells

    Amount: $208,639.00

    DESCRIPTION provided by applicant A problem with hematopoietic stem cell HSC transplantation is the risk of primary or secondary graft failure As an example in patients with hematologic maligna ...

    SBIRPhase I2016Department of Health and Human Services
  4. A Vaccine for Schistosomiasis, "SchistoShield"

    Amount: $2,540,450.00

    DESCRIPTION provided by applicant Schistosomiasis is a major neglected tropical disease of public health concern to a billion people with million currently infected and million at risk to ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  5. JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer

    Amount: $199,997.00

    Project Summary Tumors survive cancer therapy in part by blocking the entrance and permeation of drugs into the cancer We have developed a conjugatable therapeutic JOC x that selectively opens up ...

    SBIRPhase I2016Department of Health and Human Services
  6. IGF OT IGF TITLE DEVELOPMENT OF A PROPHYLACTIC ONCHOCERCIASIS VACCINE

    Amount: $441,905.00

    To develop an onchocerciasis vaccine to be used for disease control and elimination

    SBIRPhase I2016Department of Health and Human Services
  7. IGF OT IGF TITLE COMBINING PARASITE AND VECTOR COMPONENTS FOR DEVELOPMENT OF A LEISHMANIA VACCINE

    Amount: $444,428.00

    To use sandfly and parasite antigens to develop a visceral leishmaniasis vaccine

    SBIRPhase I2016Department of Health and Human Services
  8. IGF OT IGF INHALED DRUG COMBINATION FOR TUBERCULOSIS THERAPY

    Amount: $1,486,937.00

    Not Available

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  9. Tumor Tight Junction Opener + Chemotherapy Conjugates to Treat Cancer

    Amount: $191,159.00

    Project Summary Tumors survive cancer therapy in part by blocking the entrance and permeation of drugs into the cancer. We have developed a therapeutic, JO-1 , that selectively opens up tumors, which ...

    SBIRPhase I2014Department of Health and Human Services
  10. Immuno-Chemotherapy to Shorten TB Treatment

    Amount: $600,000.00

    DESCRIPTION provided by applicant Tuberculosis TB a disease caused by Mycobacterium tuberculosis Mtb is an ongoing threat to public health Globally approximately two billion people are infe ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health

Agency Micro-sites

US Flag An Official Website of the United States Government